GTx Announces Webcast of Corporate Presentation at the JP Morgan 25th Annual Healthcare Conference.MEMPHIS Memphis, city, ancient Egypt Memphis (mĕm`fĭs), ancient city of Egypt, capital of the Old Kingdom (c.3100–c.2258 B.C.), at the apex of the Nile delta and 12 mi (18 km) from Cairo. , Tenn. -- GTx, Inc. (Nasdaq: GTXI), the Men's Health Biotech Company, announced today that management will present a company overview at the JP Morgan 25th Annual Healthcare Conference at noon Pacific time on January 11, 2007. The presentation will be simultaneously webcast. The link for the live webcast is www.events.jpmorgan.com. The presentation will also be accessible from the GTx website at www.gtxinc.com. An archived replay will be available for three months beginning approximately 24 hours after the live presentation. About GTx GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens Estrogens Hormones produced by the ovaries, the female sex glands. Mentioned in: Acne, Polycystic Ovary Syndrome estrogens (es´trōjenz), n. and androgens. GTx is developing ACAPODENE[R] (toremifene citrate), a selective estrogen receptor modulator se·lec·tive estrogen receptor modulator n. Abbr. SERM A nonsteroidal compound, such as raloxifene or tamoxifen, designed to mimic the effect of estrogen on a specific tissue or body part by binding only to that part's estrogen receptors. , or SERM SERM abbr. selective estrogen receptor modulator SERM Selective estrogen receptor modulator, see there , in two separate clinical programs in men: first, a pivotal Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia Prostatic intraepithelial neoplasia (PIN) is a non-invasive lesion in the prostate gland which is though to be a precursor to prostate cancer. Microscopically, PIN is a collection of irregular cells which are fully contained within the gland structure and have not spread to , or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE[R]. GTx also is developing ostarine, a first-in-class selective androgen receptor modulator, or SARM. GTx believes that ostarine has the potential to treat a variety of indications, including cancer cachexia, end stage renal disease muscle wasting, frailty and osteoporosis. GTx plans to initiate a Phase IIb ostarine clinical trial for cancer cachexia by the summer of 2007. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion